First patient dosed in phase 2b trial of treatment for agitation in Alzheimer’s disease

IGC Pharma has announced that dosing has commenced at one of its sites participating in a phase 2b clinical trial of a combination therapy for agitation in dementia related to Alzheimer’s disease.
In a press release, the company stated that the study, currently conducted at 12 locations across the United States and Canada, will assess IGC-AD1, a combination of a CB1 receptor partial agonist with anti-neuroinflammatory properties and an inflammasome inhibitor. Dosing was initiated at ClinCloud, a clinical research facility with two locations in Florida.
The study, which is expected to

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.